Trial reportLasers in medical science2016
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study.
Trial report in Lasers in medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- A systematic review of therapeutic procedures for the treatment of morphea and systemic sclerosis.Lasers in medical science · 2026Pooled it
- Interventions for morphea.The Cochrane database of systematic reviews · 2019Pooled it
- COVID-19-associated cutaneous vasculitis with exfoliative erythroderma and extensive scarring: Long-term clinical and laser management.JAAD case reports · 2026Article
- Review
- Comparative study between fractional COArchives of dermatological research · 2025Article
- Laser-mediated Solutions: Breaking Barriers in Transdermal Drug Delivery.AAPS PharmSciTech · 2024Review
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial.Pharmaceutics · 2022Article
- Fractional Ablative Carbon Dioxide Lasers for the Treatment of Morphea: A Case Series and Literature Review.International journal of environmental research and public health · 2022Review
- Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature.Journal of clinical medicine · 2021Review
- The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review.Dermatology and therapy · 2020Article
- Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study.Health and quality of life outcomes · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphea is a rare fibrosing skin disorder that occurs as a result of abnormal homogenized collagen synthesis. Fractional ablative laser resurfacing has been used effectively in scar treatment via abnormal collagen degradation and induction of healthy collagen synthesis. Therefore, fractional ablative laser can provide an effective modality in treatment of morphea. The study aimed at evaluating the efficacy of fractional carbon dioxide laser as a new modality for the treatment of localized scleroderma and to compare its results with the well-established method of UVA-1 phototherapy. Seventeen patients with plaque and linear morphea were included in this parallel intra-individual comparative randomized controlled clinical trial. Each with two comparable morphea lesions that were randomly assigned to either 30 sessions of low-dose (30 J/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.